Hydroxychloroquine in Mild Graves' Orbitopathy

Status Recruiting

Clinical Trial Summary

This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).

Clinical Trial Description

Graves' orbitopathy (GO) is one of the common manifestations of Graves' disease (GD), which results in proptosis, eyelid retraction, soft tissue swelling, diplopia or even visual acuity impairment. In addition, mental health and quality of life are often affected. In current guidelines, limited treatment options are suggested for patients with mild GO. Recently, cell study revealed that there are multiple effects of hydroxychloroquine (HCQ) on orbital fibroblasts in patients with mild GO, including suppression of cell proliferation, adipogenesis and production of hyaluronic acid, which poses a great potential in the treatment of mild GO clinically. This randomized controlled trial is aimed to investigate the effects of HCQ in patients with mild GO on the effects of ophthalmic outcomes, quality of life, orbital volumetry on orbital computed tomography, serum inflammatory and fibrosis markers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05126147
Study type	Interventional
Source	National Taiwan University Hospital
Contact	Shyang-Rong Shih
Phone	+886-2-23123456
Email	srshih@ntu.edu.tw
Status	Recruiting
Phase	Phase 4
Start date	March 21, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05532072` - Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.	Early Phase 1
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05678374` - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Recruiting	`NCT03708627` - Bimatoprost as a Treatment for Graves' Orbitopathy	Early Phase 1
Withdrawn	`NCT01379196` - Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy	Phase 1/Phase 2
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting	`NCT06226545` - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease	Phase 2
Recruiting	`NCT01999790` - Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy	N/A
Recruiting	`NCT03066076` - Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy	Phase 3
Active, not recruiting	`NCT03122847` - Glucocorticoids and Bone in Graves' Ophthalmopathy
Terminated	`NCT01893450` - Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment	N/A
Completed	`NCT00348413` - Thyroid Treatment Trial	N/A
Completed	`NCT03498417` - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Not yet recruiting	`NCT04598815` - Sirolimus for Graves' Orbitopathy (GO)	Phase 2
Terminated	`NCT01114503` - A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease	Phase 2
Completed	`NCT05775185` - Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
Completed	`NCT05793359` - Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
Recruiting	`NCT02203682` - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy	Phase 2
Recruiting	`NCT05276063` - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3